Vanda licenses iloperidone from Novartis; Rights returned
Vanda Pharmaceuticals (genomics tools for drug discovery) has sublicensed worldwide rights from Novartis Pharma AG to develop and sell Titan Pharmaceuticals' iloperidone for schizophrenia and related psychotic disorders.
- Specialty Pharmaceuticals
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.